MorphoSys (ETR:MOR) PT Set at €65.00 by Berenberg Bank

MorphoSys (ETR:MORGet Rating) received a €65.00 ($69.15) target price from equities researchers at Berenberg Bank in a research report issued on Friday, Borsen Zeitung reports. Berenberg Bank’s price target would suggest a potential upside of 224.51% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. Deutsche Bank Rese… set a €30.00 ($31.91) price objective on MorphoSys in a research note on Wednesday, May 4th. Barclays set a €36.00 ($38.30) price objective on MorphoSys in a research note on Thursday, March 17th. Deutsche Bank Aktiengesellschaft set a €30.00 ($31.91) price objective on MorphoSys in a research note on Tuesday, March 22nd. Finally, JPMorgan Chase & Co. set a €34.00 ($36.17) price objective on MorphoSys in a research note on Tuesday, May 17th.

ETR MOR traded up €1.41 ($1.50) during mid-day trading on Friday, hitting €20.03 ($21.31). The company’s stock had a trading volume of 122,432 shares, compared to its average volume of 153,687. The company’s 50 day simple moving average is €22.19 and its 200 day simple moving average is €27.39. MorphoSys has a twelve month low of €16.45 ($17.50) and a twelve month high of €72.84 ($77.49). The company has a current ratio of 4.24, a quick ratio of 3.92 and a debt-to-equity ratio of 231.51. The firm has a market capitalization of $684.00 million and a price-to-earnings ratio of -1.14.

About MorphoSys (Get Rating)

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

See Also

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.